+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunology Market - Global Forecast 2026-2032- Product Image
Immunology Market - Global Forecast 2026-2032- Product Image
Sale

Immunology Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6140484
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Immunology Market is projected to reach USD 98.26 Billion in 2026. It is expected to continue growing at a CAGR of 8.16%, reaching USD 158.52 Billion by 2032.

Immunology: Executive Overview

Immunology encompasses the study, diagnosis, prevention, and treatment of conditions involving immune responses, immune deficiency, inflammation, and autoimmunity. Its scope spans basic research, translational science, clinical care, diagnostics, vaccines, biologic medicines, cellular approaches, and immune-monitoring technologies. The field is increasingly shaped by precision medicine, biomarker-led decision-making, and closer integration between laboratory science and routine care.

Immunology Is Shifting Toward Precision and Prevention

The landscape is moving from broad disease classification toward biologically defined patient subgroups. Advances in multi-omics, immune profiling, digital pathology, and longitudinal monitoring are improving understanding of disease heterogeneity and treatment response. At the same time, preventive immunology is gaining importance through vaccination, early risk identification, management of chronic inflammation, and strategies designed to preserve immune function across the life course. These changes are increasing the need for interoperable data, validated biomarkers, and evidence that connects biological signals with meaningful clinical outcomes.

Artificial Intelligence Is Accelerating Immunology Workflows

Artificial intelligence is being applied across immunology research and care, including image interpretation, biomarker discovery, patient stratification, protein and antibody analysis, clinical-trial recruitment, and adverse-event monitoring. Its cumulative impact depends on the quality and representativeness of training data, transparent validation, and integration into clinical workflows rather than isolated model performance. Leaders should prioritize explainability, privacy protection, bias assessment, human oversight, and prospective evaluation before using AI to support diagnosis or treatment decisions.

Regional Differences Reflect Research, Access, and Regulatory Conditions

North America combines advanced biomedical research, extensive clinical infrastructure, and substantial adoption of precision diagnostics, while access and affordability remain important considerations. Europe emphasizes collaborative research, coordinated regulation, health-system evidence, and data governance, with variation among national systems. Asia-Pacific is characterized by strong research capacity in several economies, expanding biomanufacturing, and diverse healthcare access across countries. Latin America is advancing immunization, specialty care, and research networks while facing uneven infrastructure and financing. The Middle East is investing in healthcare modernization, genomics, and specialized services, whereas Africa continues to prioritize infectious-disease control, vaccination, workforce development, and resilient diagnostic capacity.

Major International Groups Have Distinct Immunology Priorities

ASEAN countries are balancing infectious-disease priorities with growing interest in chronic immune-mediated conditions, regional research cooperation, and healthcare capacity building. BRICS members reflect varied strengths in biomedical research, manufacturing, public health, and access expansion, making collaboration and regulatory alignment important. The European Union focuses on cross-border research, data governance, coordinated health policy, and equitable access. G7 members emphasize advanced translational research, pandemic preparedness, innovation governance, and evidence-based regulation. GCC countries are strengthening specialized healthcare, genomics, and research infrastructure, while NATO members increasingly connect health resilience, biosurveillance, and preparedness with broader security planning.

Country Context Shapes Immunology Innovation and Access

Australia combines strong biomedical research with geographically dispersed service delivery. Brazil has broad public-health experience and important needs across infectious, autoimmune, and inflammatory conditions. Canada emphasizes research collaboration, public healthcare delivery, and equitable access across large geographic areas. China is expanding research, diagnostics, biomanufacturing, and clinical capabilities at scale. France, Germany, Italy, and Spain contribute substantial European research and healthcare capacity while operating within national reimbursement and regulatory contexts. India is strengthening biotechnology, diagnostics, vaccine capability, and access across a highly diverse population. Japan and South Korea pair advanced research and technology adoption with aging-population considerations. Mexico is developing specialized capacity while addressing regional disparities. Russia maintains scientific and clinical capabilities but faces constraints related to international collaboration and access to certain technologies. The United Kingdom and United States remain influential in translational research, clinical innovation, and regulatory science, alongside ongoing concerns about affordability, workforce capacity, and equitable access.

Industry Leaders Should Build Evidence, Trust, and Interoperability

Leaders should align research and product development with clearly defined immune phenotypes, clinically meaningful endpoints, and validated companion diagnostics where appropriate. They should establish multidisciplinary governance for AI and data use, invest in interoperable laboratory and clinical-data systems, and design studies that represent diverse populations and care settings. Partnerships with health systems, academic institutions, public-health agencies, and patient organizations can improve recruitment, implementation, and real-world evidence. Organizations should also strengthen supply resilience, workforce training, regulatory readiness, cybersecurity, and transparent communication about benefits, limitations, and uncertainty.

Methodology: Evidence-Led Synthesis of Immunology Trends

This executive summary uses a qualitative synthesis framework focused on established developments in immunology research, diagnostics, therapeutics, healthcare delivery, regulation, and enabling technologies. Insights are organized across global regions, international groups, and specified countries to identify recurring patterns and material differences in research capacity, public-health priorities, infrastructure, access, and governance. The analysis excludes market estimates, market sizing, market shares, forecasts, and unsupported company-specific claims. Findings should be interpreted as a strategic overview rather than a substitute for country-level clinical, regulatory, or policy assessment.

Immunology’s Next Phase Depends on Translation and Equity

Immunology is becoming more data-intensive, biologically precise, and integrated with prevention and chronic-disease management. Artificial intelligence, advanced diagnostics, immune profiling, and novel therapeutic platforms can improve discovery and care, but their value will depend on validation, responsible governance, affordability, and implementation across varied health systems. The strongest strategies will connect scientific innovation with resilient infrastructure, representative evidence, skilled workforces, and patient-centered outcomes across regions and countries.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Immunology Market, by Product Type
7.1. Introduction
7.2. Adjuvants
7.2.1. Emulsion
7.2.2. Mineral
7.2.3. Toxin Derivatives
7.3. Cell Therapy
7.3.1. Chimeric Antigen Receptor T Cell
7.3.2. Natural Killer Cell Therapy
7.3.3. Stem Cell Therapy
7.3.4. T Cell Receptor T Cell
7.4. Cytokines
7.4.1. Colony Stimulating Factors
7.4.2. Interferons
7.4.3. Interleukins
7.4.4. Tumor Necrosis Factors
7.5. Immunoassays
7.5.1. Chemiluminescent Immunoassay
7.5.2. Enzyme Linked Immunosorbent Assay
7.5.2.1. Competitive
7.5.2.2. Indirect
7.5.2.3. Sandwich
7.5.3. Lateral Flow Immunoassay
7.5.4. Radioimmunoassay
7.6. Monoclonal Antibodies
7.6.1. Chimeric
7.6.2. Fully Human
7.6.3. Humanized
7.6.4. Murine
7.7. Vaccines
7.7.1. Prophylactic
7.7.1.1. Inactivated
7.7.1.2. Live Attenuated
7.7.1.3. Subunit
7.7.2. Therapeutic
7.7.2.1. Allergen Vaccines
7.7.2.2. Cancer Vaccines
8. Immunology Market, by Therapeutic Class
8.1. Introduction
8.2. Cell Therapy
8.2.1. CAR T Cell
8.2.2. NK Cell Therapy
8.2.3. Stem Cell Therapy
8.3. Fusion Proteins
8.3.1. CTLA4 Ig
8.3.2. Interleukin Inhibitors
8.3.3. TNF Inhibitors
8.4. Monoclonal Antibodies
8.4.1. Chimeric
8.4.2. Fully Human
8.4.3. Humanized
8.4.4. Murine
8.5. Recombinant Proteins
8.5.1. Colony Stimulating Factors
8.5.2. Growth Factors
8.5.3. Interferons
8.5.4. Interleukins
8.6. Small Molecules
8.6.1. DMARDs
8.6.2. JAK Inhibitors
8.6.3. NSAIDs
8.6.4. S1P Modulators
8.7. Vaccines
8.7.1. Prophylactic
8.7.2. Therapeutic
9. Immunology Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
9.5. Topical
10. Immunology Market, by Technology
10.1. Introduction
10.2. Enzyme Linked Immunosorbent Assay
10.2.1. Competitive
10.2.2. Indirect
10.2.3. Sandwich
10.3. Flow Cytometry
10.3.1. Cell Sorting
10.3.2. Immunophenotyping
10.4. Mass Spectrometry
10.4.1. LC MS MS
10.4.2. MALDI TOF
10.5. Next Generation Sequencing
10.5.1. RNA Sequencing
10.5.2. Targeted Sequencing
10.5.3. Whole Genome Sequencing
10.6. Polymerase Chain Reaction
10.6.1. Digital PCR
10.6.2. Real Time PCR
10.6.3. RT PCR
11. Immunology Market, by Disease Indication
11.1. Introduction
11.2. Allergic
11.2.1. Allergic Rhinitis
11.2.2. Asthma
11.2.3. Atopic Dermatitis
11.3. Autoimmune
11.3.1. Inflammatory Bowel Disease
11.3.2. Lupus
11.3.3. Multiple Sclerosis
11.3.4. Psoriasis
11.3.5. Rheumatoid Arthritis
11.4. Infectious
11.4.1. COVID-19
11.4.2. Hepatitis
11.4.3. HIV
11.4.4. Tuberculosis
11.5. Oncology
11.5.1. Hematological Malignancies
11.5.1.1. Leukemia
11.5.1.2. Lymphoma
11.5.1.3. Multiple Myeloma
11.5.2. Solid Tumors
11.5.2.1. Breast Cancer
11.5.2.2. Colorectal Cancer
11.5.2.3. Lung Cancer
11.5.2.4. Prostate Cancer
12. Immunology Market, by Application
12.1. Introduction
12.2. Diagnostics
12.2.1. Histopathology
12.2.2. Immunoassays
12.2.3. Molecular Diagnostics
12.2.3.1. Mass Spectrometry
12.2.3.2. Next Generation Sequencing
12.2.3.3. Polymerase Chain Reaction
12.3. Monitoring
12.3.1. Biomarker Monitoring
12.3.2. Therapeutic Drug Monitoring
12.4. Research
12.4.1. Clinical Research
12.4.2. Preclinical Research
12.4.3. Translational Research
12.5. Therapeutics
13. Immunology Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Diagnostic Laboratories
13.4. Hospitals
13.5. Research Laboratories
14. Immunology Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. Immunology Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. Immunology Market, by Country
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc.
18.2. Amgen Inc.
18.3. Astellas Pharma Inc.
18.4. AstraZeneca PLC
18.5. Bayer AG
18.6. Biogen Inc.
18.7. Bristol-Myers Squibb Company
18.8. Cipla Ltd.
18.9. Dr. Reddy's Laboratories Ltd.
18.10. Eli Lilly and Company
18.11. Gilead Sciences, Inc.
18.12. GlaxoSmithKline plc
18.13. Incyte Corporation
18.14. Johnson & Johnson Services, Inc.
18.15. Lupin Limited
18.16. Merck & Co., Inc.
18.17. Novartis AG
18.18. Novo Nordisk A/S
18.19. Organon & Co.
18.20. Pfizer Inc.
18.21. Roche Holding AG
18.22. Sanofi S.A.
18.23. Sun Pharmaceutical Industries Ltd.
18.24. Takeda Pharmaceutical Company Limited
18.25. Teva Pharmaceutical Industries Ltd.
18.26. UCB Pharma S.A.
18.27. Vertex Pharmaceuticals Incorporated
18.28. Wockhardt Ltd.
18.29. Zydus Lifesciences Ltd.
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global Immunology Market, Years Considered for the Study
FIGURE 2. Global Immunology Market, Research Design
FIGURE 3. Global Immunology Market, Research Framework
FIGURE 4. Global Immunology Market, Data Triangulation
FIGURE 5. Global Immunology Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Immunology Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Immunology Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Immunology Market Size, by Therapeutic Class, 2025 vs 2032 (%)
FIGURE 9. Global Immunology Market Size, by Therapeutic Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Immunology Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Immunology Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Immunology Market Size, by Technology, 2025 vs 2032 (%)
FIGURE 13. Global Immunology Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Immunology Market Size, by Disease Indication, 2025 vs 2032 (%)
FIGURE 15. Global Immunology Market Size, by Disease Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Immunology Market Size, by Application, 2025 vs 2032 (%)
FIGURE 17. Global Immunology Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Immunology Market Size, by End User, 2025 vs 2032 (%)
FIGURE 19. Global Immunology Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Immunology Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global Immunology Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Immunology Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Immunology Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global Immunology Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Immunology Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Immunology Market Segmentation & Coverage
TABLE 2. Global Immunology Market Size, 2017-2032 (USD Million)
TABLE 3. Global Immunology Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Adjuvants Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Adjuvants Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Adjuvants Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Emulsion Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Emulsion Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Emulsion Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Mineral Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Mineral Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Mineral Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Toxin Derivatives Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Toxin Derivatives Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Toxin Derivatives Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Chimeric Antigen Receptor T Cell Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Chimeric Antigen Receptor T Cell Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Chimeric Antigen Receptor T Cell Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Natural Killer Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Natural Killer Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Natural Killer Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Stem Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Stem Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Stem Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global T Cell Receptor T Cell Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global T Cell Receptor T Cell Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global T Cell Receptor T Cell Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Cytokines Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Cytokines Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Cytokines Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Colony Stimulating Factors Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Colony Stimulating Factors Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Colony Stimulating Factors Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Interferons Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Interferons Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Interferons Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Interleukins Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Interleukins Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Interleukins Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Tumor Necrosis Factors Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Tumor Necrosis Factors Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Tumor Necrosis Factors Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Immunoassays Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Immunoassays Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Immunoassays Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Chemiluminescent Immunoassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Chemiluminescent Immunoassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Chemiluminescent Immunoassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Enzyme Linked Immunosorbent Assay Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Enzyme Linked Immunosorbent Assay Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Enzyme Linked Immunosorbent Assay Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Competitive Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Competitive Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Competitive Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Indirect Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Indirect Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Indirect Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Sandwich Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Sandwich Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Sandwich Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Lateral Flow Immunoassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Lateral Flow Immunoassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Lateral Flow Immunoassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Radioimmunoassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Radioimmunoassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Radioimmunoassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Chimeric Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Chimeric Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Chimeric Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Fully Human Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Fully Human Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Fully Human Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Humanized Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Humanized Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Humanized Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Murine Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Murine Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Murine Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Prophylactic Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Prophylactic Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Prophylactic Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Inactivated Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Inactivated Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Inactivated Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Live Attenuated Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Live Attenuated Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Live Attenuated Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Subunit Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Subunit Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Subunit Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Therapeutic Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Therapeutic Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Therapeutic Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Allergen Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Allergen Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Allergen Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Cancer Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Cancer Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Cancer Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Immunology Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 110. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global CAR T Cell Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Global CAR T Cell Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. Global CAR T Cell Market Size, by Country, 2017-2032 (USD Million)
TABLE 116. Global NK Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global NK Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global NK Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Stem Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Stem Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Stem Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Fusion Proteins Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Fusion Proteins Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Fusion Proteins Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global CTLA4 Ig Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global CTLA4 Ig Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global CTLA4 Ig Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Interleukin Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Interleukin Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Interleukin Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global TNF Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global TNF Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global TNF Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global Chimeric Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Chimeric Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Chimeric Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Fully Human Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Global Fully Human Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. Global Fully Human Market Size, by Country, 2017-2032 (USD Million)
TABLE 143. Global Humanized Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Global Humanized Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. Global Humanized Market Size, by Country, 2017-2032 (USD Million)
TABLE 146. Global Murine Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Global Murine Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. Global Murine Market Size, by Country, 2017-2032 (USD Million)
TABLE 149. Global Recombinant Proteins Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Global Recombinant Proteins Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. Global Recombinant Proteins Market Size, by Country, 2017-2032 (USD Million)
TABLE 152. Global Colony Stimulating Factors Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. Global Colony Stimulating Factors Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. Global Colony Stimulating Factors Market Size, by Country, 2017-2032 (USD Million)
TABLE 155. Global Growth Factors Market Size, by Region, 2017-2032 (USD Million)
TABLE 156. Global Growth Factors Market Size, by Group, 2017-2032 (USD Million)
TABLE 157. Global Growth Factors Market Size, by Country, 2017-2032 (USD Million)
TABLE 158. Global Interferons Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. Global Interferons Market Size, by Group, 2017-2032 (USD Million)
TABLE 160. Global Interferons Market Size, by Country, 2017-2032 (USD Million)
TABLE 161. Global Interleukins Market Size, by Region, 2017-2032 (USD Million)
TABLE 162. Global Interleukins Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. Global Interleukins Market Size, by Country, 2017-2032 (USD Million)
TABLE 164. Global Small Molecules Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. Global Small Molecules Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. Global Small Molecules Market Size, by Country, 2017-2032 (USD Million)
TABLE 167. Global DMARDs Market Size, by Region, 2017-2032 (USD Million)
TABLE 168. Global DMARDs Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. Global DMARDs Market Size, by Country, 2017-2032 (USD Million)
TABLE 170. Global JAK Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 171. Global JAK Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. Global JAK Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 173. Global NSAIDs Market Size, by Region, 2017-2032 (USD Million)
TABLE 174. Global NSAIDs Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. Global NSAIDs Market Size, by Country, 2017-2032 (USD Million)
TABLE 176. Global S1P Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 177. Global S1P Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. Global S1P Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 179. Global Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 180. Global Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 181. Global Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 182. Global Prophylactic Market Size, by Region, 2017-2032 (USD Million)
TABLE 183. Global Prophylactic Market Size, by Group, 2017-2032 (USD Million)
TABLE 184. Global Prophylactic Market Size, by Country, 2017-2032 (USD Million)
TABLE 185. Global Therapeutic Market Size, by Region, 2017-2032 (USD Million)
TABLE 186. Global Therapeutic Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. Global Therapeutic Market Size, by Country, 2017-2032 (USD Million)
TABLE 188. Global Immunology Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 189. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 190. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 191. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 192. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 193. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 194. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 195. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 196. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 197. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 198. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 199. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 201. Global Immunology Market Size, by Technology, 2017-2032 (USD Million)
TABLE 202. Global Enzyme Linked Immunosorbent Assay Market Size, by Region, 2017-2032 (USD Million)
TABLE 203. Global Enzyme Linked Immunosorbent Assay Market Size, by Group, 2017-2032 (USD Million)
TABLE 204. Global Enzyme Linked Immunosorbent Assay Market Size, by Country, 2017-2032 (USD Million)
TABLE 205. Global Competitive Market Size, by Region, 2017-2032 (USD Million)
TABLE 206. Global Competitive Market Size, by Group, 2017-2032 (USD Million)
TABLE 207. Global Competitive Market Size, by Country, 2017-2032 (USD Million)
TABLE 208. Global Indirect Market Size, by Region, 2017-2032 (USD Million)
TABLE 209. Global Indirect Market Size, by Group, 2017-2032 (USD Million)
TABLE 210. Global Indirect Market Size, by Country, 2017-2032 (USD Million)
TABLE 211. Global Sandwich Market Size, by Region, 2017-2032 (USD Million)
TABLE 212. Global Sandwich Market Size, by Group, 2017-2032 (USD Million)
TABLE 213. Global Sandwich Market Size, by Country, 2017-2032 (USD Million)
TABLE 214. Global Flow Cytometry Market Size, by Region, 2017-2032 (USD Million)
TABLE 215. Global Flow Cytometry Market Size, by Group, 2017-2032 (USD Million)
TABLE 216. Global Flow Cytometry Market Size, by Country, 2017-2032 (USD Million)
TABLE 217. Global Cell Sorting Market Size, by Region, 2017-2032 (USD Million)
TABLE 218. Global Cell Sorting Market Size, by Group, 2017-2032 (USD Million)
TABLE 219. Global Cell Sorting Market Size, by Country, 2017-2032 (USD Million)
TABLE 220. Global Immunophenotyping Market Size, by Region, 2017-2032 (USD Million)
TABLE 221. Global Immunophenotyping Market Size, by Group, 2017-2032 (USD Million)
TABLE 222. Global Immunophenotyping Market Size, by Country, 2017-2032 (USD Million)
TABLE 223. Global Mass Spectrometry Market Size, by Region, 2017-2032 (USD Million)
TABLE 224. Global Mass Spectrometry Market Size, by Group, 2017-2032 (USD Million)
TABLE 225. Global Mass Spectrometry Market Size, by Country, 2017-2032 (USD Million)
TABLE 226. Global LC MS MS Market Size, by Region, 2017-2032 (USD Million)
TABLE 227. Global LC MS MS Market Size, by Group, 2017-2032 (USD Million)
TABLE 228. Global LC MS MS Market Size, by Country, 2017-2032 (USD Million)
TABLE 229. Global MALDI TOF Market Size, by Region, 2017-2032 (USD Million)
TABLE 230. Global MALDI TOF Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. Global MALDI TOF Market Size, by Country, 2017-2032 (USD Million)
TABLE 232. Global Next Generation Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 233. Global Next Generation Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 234. Global Next Generation Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 235. Global RNA Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 236. Global RNA Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 237. Global RNA Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 238. Global Targeted Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 239. Global Targeted Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 240. Global Targeted Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 241. Global Whole Genome Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 242. Global Whole Genome Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 243. Global Whole Genome Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 244. Global Polymerase Chain Reaction Market Size, by Region, 2017-2032 (USD Million)
TABLE 245. Global Polymerase Chain Reaction Market Size, by Group, 2017-2032 (USD Million)
TABLE 246. Global Polymerase Chain Reaction Market Size, by Country, 2017-2032 (USD Million)
TABLE 247. Global Digital PCR Market Size, by Region, 2017-2032 (USD Million)
TABLE 248. Global Digital PCR Market Size, by Group, 2017-2032 (USD Million)
TABLE 249. Global Digital PCR Market Size, by Country, 2017-2032 (USD Million)
TABLE 250. Global Real Time PCR Market Size, by Region, 2017-2032 (USD Million)
TABLE 251. Global Real Time PCR Market Size, by Group, 2017-2032 (USD Million)
TABLE 252. Global Real Time PCR Market Size, by Country, 2017-2032 (USD Million)
TABLE 253. Global RT PCR Market Size, by Region, 2017-2032 (USD Million)
TABLE 254. Global RT PCR Market Size, by Group, 2017-2032 (USD Million)
TABLE 255. Global RT PCR Market Size, by Country, 2017-2032 (USD Million)
TABLE 256. Global Immunology Market Size, by Disease Indication, 2017-2032 (USD Million)
TABLE 257. Global Allergic Market Size, by Region, 2017-2032 (USD Million)
TABLE 258. Global Allergic Market Size, by Group, 2017-2032 (USD Million)
TABLE 259. Global Allergic Market Size, by Country, 2017-2032 (USD Million)
TABLE 260. Global Allergic Rhinitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 261. Global Allergic Rhinitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 262. Global Allergic Rhinitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 263. Global Asthma Market Size, by Region, 2017-2032 (USD Million)
TABLE 264. Global Asthma Market Size, by Group, 2017-2032 (USD Million)
TABLE 265. Global Asthma Market Size, by Country, 2017-2032 (USD Million)
TABLE 266. Global Atopic Dermatitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 267. Global Atopic Dermatitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 268. Global Atopic Dermatitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 269. Global Autoimmune Market Size, by Region, 2017-2032 (USD Million)
TABLE 270. Global Autoimmune Market Size, by Group, 2017-2032 (USD Million)
TABLE 271. Global Autoimmune Market Size, by Country, 2017-2032 (USD Million)
TABLE 272. Global Inflammatory Bowel Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 273. Global Inflammatory Bowel Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 274. Global Inflammatory Bowel Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 275. Global Lupus Market Size, by Region, 2017-2032 (USD Million)
TABLE 276. Global Lupus Market Size, by Group, 2017-2032 (USD Million)
TABLE 277. Global Lupus Market Size, by Country, 2017-2032 (USD Million)
TABLE 278. Global Multiple Sclerosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 279. Global Multiple Sclerosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 280. Global Multiple Sclerosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 281. Global Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 282. Global Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 283. Global Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 284. Global Rheumatoid Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 285. Global Rheumatoid Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 286. Global Rheumatoid Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 287. Global Infectious Market Size, by Region, 2017-2032 (USD Million)
TABLE 288. Global Infectious Market Size, by Group, 2017-2032 (USD Million)
TABLE 289. Global Infectious Market Size, by Country, 2017-2032 (USD Million)
TABLE 290. Global COVID-19 Market Size, by Region, 2017-2032 (USD Million)
TABLE 291. Global COVID-19 Market Size, by Group, 2017-2032 (USD Million)
TABLE 292. Global COVID-19 Market Size, by Country, 2017-2032 (USD Million)
TABLE 293. Global Hepatitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 294. Global Hepatitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 295. Global Hepatitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 296. Global HIV Market Size, by Region, 2017-2032 (USD Million)
TABLE 297. Global HIV Market Size, by Group, 2017-2032 (USD Million)
TABLE 298. Global HIV Market Size, by Country, 2017-2032 (USD Million)
TABLE 299. Global Tuberculosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 300. Global Tuberculosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 301. Global Tuberculosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 302. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 303. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 304. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 305. Global Hematological Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 306. Global Hematological Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 307. Global Hematological Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 308. Global Leukemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 309. Global Leukemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 310. Global Leukemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 311. Global Lymphoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 312. Global Lymphoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 313. Global Lymphoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 314. Global Multiple Myeloma Market Size, by Region, 2017-2032 (USD Million)
TABLE 315. Global Multiple Myeloma Market Size, by Group, 2017-2032 (USD Million)
TABLE 316. Global Multiple Myeloma Market Size, by Country, 2017-2032 (USD Million)
TABLE 317. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 318. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 319. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 320. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 321. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 322. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 323. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 324. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 325. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 326. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 327. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 328. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 329. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 330. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 331. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 332. Global Immunology Market Size, by Application, 2017-2032 (USD Million)
TABLE 333. Global Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 334. Global Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 335. Global Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 336. Global Histopathology Market Size, by Region, 2017-2032 (USD Million)
TABLE 337. Global Histopathology Market Size, by Group, 2017-2032 (USD Million)
TABLE 338. Global Histopathology Market Size, by Country, 2017-2032 (USD Million)
TABLE 339. Global Immunoassays Market Size, by Region, 2017-2032 (USD Million)
TABLE 340. Global Immunoassays Market Size, by Group, 2017-2032 (USD Million)
TABLE 341. Global Immunoassays Market Size, by Country, 2017-2032 (USD Million)
TABLE 342. Global Molecular Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 343. Global Molecular Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 344. Global Molecular Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 345. Global Mass Spectrometry Market Size, by Region, 2017-2032 (USD Million)
TABLE 346. Global Mass Spectrometry Market Size, by Group, 2017-2032 (USD Million)
TABLE 347. Global Mass Spectrometry Market Size, by Country, 2017-2032 (USD Million)
TABLE 348. Global Next Generation Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 349. Global Next Generation Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 350. Global Next Generation Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 351. Global Polymerase Chain Reaction Market Size, by Region, 2017-2032 (USD Million)
TABLE 352. Global Polymerase Chain Reaction Market Size, by Group, 2017-2032 (USD Million)
TABLE 353. Global Polymerase Chain Reaction Market Size, by Country, 2017-2032 (USD Million)
TABLE 354. Global Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 355. Global Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 356. Global Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 357. Global Biomarker Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 358. Global Biomarker Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 359. Global Biomarker Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 360. Global Therapeutic Drug Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 361. Global Therapeutic Drug Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 362. Global Therapeutic Drug Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 363. Global Research Market Size, by Region, 2017-2032 (USD Million)
TABLE 364. Global Research Market Size, by Group, 2017-2032 (USD Million)
TABLE 365. Global Research Market Size, by Country, 2017-2032 (USD Million)
TABLE 366. Global Clinical Research Market Size, by Region, 2017-2032 (USD Million)
TABLE 367. Global Clinical Research Market Size, by Group, 2017-2032 (USD Million)
TABLE 368. Global Clinical Research Market Size, by Country, 2017-2032 (USD Million)
TABLE 369. Global Preclinical Research Market Size, by Region, 2017-2032 (USD Million)
TABLE 370. Global Preclinical Research Market Size, by Group, 2017-2032 (USD Million)
TABLE 371. Global Preclinical Research Market Size, by Country, 2017-2032 (USD Million)
TABLE 372. Global Translational Research Market Size, by Region, 2017-2032 (USD Million)
TABLE 373. Global Translational Research Market Size, by Group, 2017-2032 (USD Million)
TABLE 374. Global Translational Research Market Size, by Country, 2017-2032 (USD Million)
TABLE 375. Global Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 376. Global Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 377. Global Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 378. Global Immunology Market Size, by End User, 2017-2032 (USD Million)
TABLE 379. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 380. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 381. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 382. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 383. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 384. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 385. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 386. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 387. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 388. Global Research Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 389. Global Research Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 390. Global Research Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 391. Global Immunology Market Size, by Region, 2017-2032 (USD Million)
TABLE 392. Asia-Pacific Immunology Market Size, by Region, 2017-2032 (USD Million)
TABLE 393. Asia-Pacific Immunology Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 394. Asia-Pacific Immunology Market Size, by Adjuvants, 2017-2032 (USD Million)
TABLE 395. Asia-Pacific Immunology Market Size, by Cell Therapy, 2017-2032 (USD Million)
TABLE 396. Asia-Pacific Immunology Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 397. Asia-Pacific Immunology Market Size, by Immunoassays, 2017-2032 (USD Million)
TABLE 398. Asia-Pacific Immunology Market Size, by Enzyme Linked Immunosorbent Assay, 2017-2032 (USD Million)
TABLE 399. Asia-Pacific Immunology Market Size, by Monoclonal Antibodies, 2017-2032 (USD Million)
TABLE 400. Asia-Pacific Immunology Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 401. Asia-Pacific Immunology Market Size, by Prophylactic, 2017-2032 (USD Million)
TABLE 402. Asia-Pacific Immunology Market Size, by Therapeutic, 2017-2032 (USD Million)
TABLE 403. Asia-Pacific Immunology Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 404. Asia-Pacific Immunology Market Size, by Cell Th

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Organon & Co.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma S.A.
  • Vertex Pharmaceuticals Incorporated
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.

Related Topics

Related Reports

Biochemistry & Immunology Integrated Analyzer Market - Global Forecast 2026-2032 - Product Image

Biochemistry & Immunology Integrated Analyzer Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Flow Cytometry in Oncology & Immunology Market - Global Forecast 2026-2032 - Product Image

Flow Cytometry in Oncology & Immunology Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Immunology Market - Global Strategic Business Report - Product Image

Immunology Market - Global Strategic Business Report

  • Report
  • 374 Pages
  • Global
From
Immunology Biosimilars Market Report 2026 - Product Image

Immunology Biosimilars Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Flow Cytometry in Oncology and Immunology Market Report 2026 - Product Image

Flow Cytometry in Oncology and Immunology Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.